Pazopanib was significantly more inhibitory to a HER2 transfectant of MCF7 breast carcinoma cells in vivo than the parental cell line, confirming that HER2 activation of wild type B-Raf is a sensitive target for this drug. The gene discussed is ERBB2; the disease is breast carcinoma.